TAK Investors, You Need to Know These Facts Today.

By Kim Brooks • Tuesday, July 01 09:59 • Permanent Link

Large-cap Health Care company Takeda Pharmaceutical has moved -0.1% so far today on a volume of 334,438, compared to its average of 2,272,818. In contrast, the S&P 500 index moved -0.0%.

Takeda Pharmaceutical trades -10.71% away from its average analyst target price of $17.3 per share. The 4 analysts following the stock have set target prices ranging from $15.768804 to $19.217672, and on average have given Takeda Pharmaceutical a rating of buy.

If you are considering an investment in TAK, you'll want to know the following:

Takeda Pharmaceutical's current price is -99.5% below its Graham number of $2971.95, which implies the stock has a margin of safety
Takeda Pharmaceutical has moved 18.6% over the last year, and the S&P 500 logged a change of 12.6%
Based on its trailing earnings per share of 0.23, Takeda Pharmaceutical has a trailing 12 month Price to Earnings (P/E) ratio of 67.2 while the S&P 500 average is 29.3
TAK has a forward P/E ratio of 29.2 based on its forward 12 month price to earnings (EPS) of $0.53 per share
Its Price to Book (P/B) ratio is 0.0 compared to its sector average of 3.19
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally.
Based in Tokyo, the company has 47,455 full time employees and a market cap of $48.26 Billion. Takeda Pharmaceutical currently returns an annual dividend yield of 1267.8%.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.